Table of Content

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview
Overview
Market and Technology Background
A Brief History of CAR T-Cell Therapy
FDA Product Approvals
Other CAR T-Cell Therapies
Clinical Applications of CAR T-Cell Therapy
Adoptive Cell Transfer (ACT) Technologies

Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Increasing Incidence of Cancer
Growing Investments and Funding in CAR T-Cell Therapy Research
Robust R&D Pipeline
Advances in Genetic Engineering
Market Restraints
Complex Legislative and Regulatory Procedures
Alternative Products from Competitors
Market Opportunities
Growing Significance of Precision Medicine
Expanding Applications for CAR T-Cell Therapy
Market Challenges
Complex Manufacturing and Supply Chain
Reimbursement Challenges for CAR T-Cell Therapy

Chapter 4 Emerging Technologies and Clinical Trials
Introduction
Clinical Trials Being Conducted Globally
Distribution of CAR T-Cell Clinical Trials in China

Chapter 5 Market Segmentation Analysis
Key Takeaways
Segmentation Breakdown
Global Market for CAR T-Cell Therapy, by Product
Yescarta
Kymriah
Tecartus
Abecma
Breyanzi
Carvykti
Global Market for CAR T-Cell Therapy, by Indication
Geographic Breakdown
Global Market for CAR T-Cell Therapy, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 Patent Review and New Developments
Introduction
Anticipated Increase in Patent Litigation on Customized Patient Treatments
Company-specific Intellectual Property and Patent Information
Amgen
Avacta Life Sciences Ltd.
Bluebird Bio
Celgene Corp.
Cellectis
Celyad SA
Editas Medicine Inc.
Eureka Therapeutics Inc.
iCell Gene Therapeutics
Juno Therapeutics Inc. (A Celgene Co.)
Noile-Immune Biotech
Novartis AG

Chapter 7 Competitive Intelligence
Ranking of Leading Players
Strategic Considerations

Chapter 8 Sustainability in the CAR T-Cell Therapy Market: ESG Perspective
Introduction to ESG
Role of ESG in the Pharma Industry
ESG Performance Analysis
Environmental
Social
Governance
ESG Risk Ratings
Conclusion

Chapter 9 Appendix
Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
ALLOGENE THERAPEUTICS
AMGEN INC.
ASTRAZENECA
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
CELLECTIS S.A.
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
ICELL GENE THERAPEUTICS INC.
JOHNSON & JOHNSON SERVICES INC.
LES LABORATOIRES SERVIER
NOVARTIS AG
PFIZER INC.
PROTHERAGEN INC.



List of Figures

Summary Figure : Global Market for CAR T-Cell Therapy, by Product, 2022–2029
Figure 1 : Historical Development of CAR T-Cell Therapy, 1992–2017
Figure 2 : Snapshot of the Market Dynamics for CAR T-Cell Therapy
Figure 3 : Estimated New Cancer Cases, 2022, 2045 and 2050
Figure 4 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Status, January 2023
Figure 5 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Study Phase, January 2023
Figure 6 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Investigator Type, January 2023
Figure 7 : Global CAR T-Cell Clinical Trial Activity, by Study Start Date and Phase, 2021–2024
Figure 8 : Global Market Shares of CAR T-Cell Therapy, by Product, 2024
Figure 9 : Global Market Shares for Yescarta, by Region, 2024
Figure 10 : Global Market Shares for Kymriah, by Region, 2024
Figure 11 : Global Market Shares for Tecartus, by Region, 2024
Figure 12 : Global Market Shares for Abecma, by Region, 2024
Figure 13 : Global Market Shares for Breyanzi, by Region, 2024
Figure 14 : Global Market Shares for Carvykti, by Region, 2024
Figure 15 : Global Market Shares of CAR T-Cells Therapy, by Indication, 2024
Figure 16 : Global Market Shares of CAR T-Cell Therapy, by Region, 2024
Figure 17 : Strategic Considerations
Figure 18 : How a Strong ESG Proposition Benefits Businesses
Figure 19 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 20 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 21 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
Figure 22 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 23 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
Figure 24 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
Figure 25 : Bristol Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
Figure 26 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 27 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 28 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 29 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
Figure 30 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
Figure 31 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 32 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 33 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 34 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023

List of Tables

Summary Table : Global Market for CAR T-Cell Therapy, by Product, Through 2029
Table 1 : U.S. FDA-approved CAR T-cell Therapies, 2017–2022
Table 2 : Summary Classification of Tumors of the Hematopoietic and Lymphoid Tissues
Table 3 : Tumor-Associated Antigens of CAR T-Cell Targets
Table 4 : Global Cancer Statistics, 2022
Table 5 : Clinical Trials of CAR T-Cell Therapy, by Select Countries, January 2023
Table 6 : CAR T-Cell Therapy Clinical Trials Distribution, by Investigators and Collaborators, January 2023
Table 7 : Emerging CAR T-Cell Therapy Clinical Trials, by Company
Table 8 : Clinical Trials on CD19 Directed CAR T Cells in the U.S.
Table 9 : Examples of Clinical Trials on CD19-Directed CAR T Cells in China
Table 10 : Examples of Clinical Trials on CAR T Cells Targeting Non-CD19 Antigens in China
Table 11 : Examples of Clinical Trials on CAR T Cells for Solid Tumors in China
Table 12 : Clinical Trials on CAR T Cells with Fourth-Generation CARs in China
Table 13 : Global Market for CAR T-Cell Therapy, by Product, Through 2029
Table 14 : Global Market for CAR T-Cell Therapy, by Indication, Through 2029
Table 15 : Clinical Trials of CAR T-cell Therapy in Other Indications
Table 16 : Global Market for CAR T-Cell Therapy, by Region, Through 2029
Table 17 : Bluebird Bio: Patents and Patent Applications, 2012–2021
Table 18 : Celgene Corp.: Patents and Patent Applications, 2018–2021
Table 19 : Cellectis: Patents and Patent Applications, 2018–2021
Table 20 : Editas Medicine: Patent Applications, 2015–2021
Table 21 : Eureka Therapeutics: Patent Applications, 2012–2021
Table 22 : iCell Gene Therapeutics: Patent Applications, 2017–2019
Table 23 : Juno Therapeutics Inc. and Memorial Sloan Kettering Cancer Center: Patents and Patent Applications, 2000–2021
Table 24 : Noile-Immune Biotech Inc. Yamaguchi University Patent Applications, 2017
Table 25 : Novartis AG and University of Pennsylvania: Patents and Patent Applications, 2013–2021
Table 26 : Leading Companies in the CAR T-Cell Therapy Market, 2023
Table 27 : Focus Areas in ESG Metrics
Table 28 : ESG Risk Rankings for CAR T-Cell Therapy Companies, 2024*
Table 29 : Abbreviations Used in this Report
Table 30 : AbbVie Inc.: Company Snapshot
Table 31 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 32 : AbbVie Inc.: Product Portfolio
Table 33 : AbbVie Inc.: News/Key Developments, 2023–2024
Table 34 : Allogene Therapeutics: Company Snapshot
Table 35 : Allogene Therapeutics: Financial Performance, FY 2022 and 2023
Table 36 : Allogene Therapeutics: Product Portfolio
Table 37 : Allogene Therapeutics: News/Key Developments, 2024
Table 38 : Amgen Inc.: Company Snapshot
Table 39 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 40 : Amgen Inc.: Product Portfolio
Table 41 : Amgen Inc.: News/Key Developments, 2024
Table 42 : AstraZeneca: Company Snapshot
Table 43 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 44 : AstraZeneca: Product Portfolio
Table 45 : AstraZeneca: News/Key Developments, 2023–2024
Table 46 : Bluebird Bio Inc.: Company Snapshot
Table 47 : Bluebird Bio Inc.: Financial Performance, FY 2022 and 2023
Table 48 : Bluebird Bio Inc.: Product Portfolio
Table 49 : Bluebird Bio Inc.: News/Key Developments, 2020-2022
Table 50 : Bristol-Myers Squibb Co.: Company Snapshot
Table 51 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 52 : Bristol-Myers Squibb Co.: Product Portfolio
Table 53 : Bristol-Myers Squibb Co.: News/Key Developments, 2023–2024
Table 54 : Cellectis S.A.: Company Snapshot
Table 55 : Cellectis S.A.: Financial Performance, FY 2022 and 2023
Table 56 : Cellectis S.A.: Product Portfolio
Table 57 : Cellectis S.A.: News/Key Developments, 2023–2024
Table 58 : Eureka Therapeutics Inc.: Company Snapshot
Table 59 : Eureka Therapeutics Inc: Product Portfolio
Table 60 : Eureka Therapeutics Inc.: News/Key Developments, 2023–2024
Table 61 : Gilead Sciences Inc.: Company Snapshot
Table 62 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 63 : Gilead Sciences Inc.: Product Portfolio
Table 64 : Gilead Sciences Inc.: News/Key Developments, 2022–2024
Table 65 : iCell Gene Therapeutics Inc.: Company Snapshot
Table 66 : iCell Gene Therapeutics Inc: Product Portfolio
Table 67 : iCell Gene Therapeutics Inc.: News/Key Developments, 2024
Table 68 : Johnson & Johnson Services Inc.: Company Snapshot
Table 69 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 70 : Johnson & Johnson Services Inc.: Product Portfolio
Table 71 : Johnson & Johnson Services Inc.: News/Key Developments, 2022–2024
Table 72 : Les Laboratoires Servier: Company Snapshot
Table 73 : Les Laboratoires Servier: Product Portfolio
Table 74 : Les Laboratoires Servier: News/Key Developments, 2024
Table 75 : Novartis AG: Company Snapshot
Table 76 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 77 : Novartis AG: Product Portfolio
Table 78 : Novartis AG: News/Key Developments, 2021–2024
Table 79 : Pfizer Inc.: Company Snapshot
Table 80 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 81 : Pfizer Inc.: Product Portfolio
Table 82 : Pfizer Inc.: News/Key Developments, 2023
Table 83 : Protheragen Inc.: Company Snapshot
Table 84 : Protheragen Inc.: Product Portfolio